EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Ribociclib (Lee011), CAS#1374639-75-4, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 1KG in stock, pls check:
Name:Ribociclib (Lee011)
CAS#: 1374639-75-4
Formula: C27H36N8O5
Exact Mass:
Molecular Weight: 552.636
Elemental Analysis: C, 58.68; H, 6.57; N, 20.28; O, 14.48
Exact Mass:
Molecular Weight: 552.636
Elemental Analysis: C, 58.68; H, 6.57; N, 20.28; O, 14.48
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Ribociclib (Lee011) Intermediates:
1. Ribociclib (Lee011) Intermediate:4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester
1. Ribociclib (Lee011) Intermediate:4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester
Cas#571188-59-5,
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
2. Ribociclib (Lee011) Intermediate:5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine
Cas#733039-20-8,
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
3. Ribociclib (Lee011) Intermediate:(2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol
Cas#1374639-77-6
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
4. Ribociclib (Lee011) Intermediate:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
Cas#1211443-61-6
Cas#1211443-61-6
We have more than 1kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
1: Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. PubMed PMID: 27717303.
2: Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. PubMed PMID: 27336726.
3: Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. PubMed PMID: 27542767.
4: Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Review. PubMed PMID: 27493615; PubMed Central PMCID: PMC4960359.
5: Ribociclib Lengthens Breast Cancer Survival. Cancer Discov. 2016 Dec;6(12):1299. PubMed PMID: 27810861.
6: Aristizabal Prada ET, Noelting S, Spoettl G, Maurer J, Auernhammer CJ. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology. 2017 Feb 23. doi: 10.1159/000463386. [Epub ahead of print] PubMed PMID: 28226315.
7: de Gramont A, Herrera A, de Gramont A. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288-289. PubMed PMID: 28102649.
8: Araki K, Miyoshi Y. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288. PubMed PMID: 28102647.
9: Hortobagyi GN. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):289. doi: 10.1056/NEJMc1615255. PubMed PMID: 28099830.
10: Burki TK. Ribociclib in HR-positive, HER2-negative breast cancer. Lancet Oncol. 2016 Nov;17(11):e482. doi: 10.1016/S1470-2045(16)30502-2. PubMed PMID: 27746106.
11: Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, Wei W, Dugger TC, Knudsen E, Arteaga CL. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017 Mar 1. pii: canres.2653.2016. doi: 10.1158/0008-5472.CAN-16-2653. [Epub ahead of print] PubMed PMID: 28249908.
12: Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V. [Cell cycle inhibitors in endocrine receptor positive breast cancer]. Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. French. PubMed PMID: 28126188.
13: Wood A, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King F, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris J, Mosse YP. Dual ALK and CDK4/6 inhibition demonstrates on-target synergy against neuroblastoma. Clin Cancer Res. 2016 Dec 16. pii: clincanres.1114.2016. [Epub ahead of print] PubMed PMID: 27986745.
14: Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin Cancer Res. 2016 Oct 11. doi: 10.1158/1078-0432.CCR-16-1131. [Epub ahead of print] PubMed PMID: 27729458.
15: Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015 Dec 18;10(12):2680-6. doi: 10.1021/acschembio.5b00368. PubMed PMID: 26390342; PubMed Central PMCID: PMC4684772.
16: O'Sullivan CC. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opin Pharmacother. 2016 Aug;17(12):1657-67. doi: 10.1080/14656566.2016.1201072. Review. PubMed PMID: 27322766.
17: Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb;16(1):8-17. doi: 10.1016/j.clbc.2015.07.005. Review. PubMed PMID: 26303211.
18: Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Review. PubMed PMID: 27017286.
19: Konecny GE. Cyclin-dependent kinase pathways as targets for women's cancer treatment. Curr Opin Obstet Gynecol. 2016 Feb;28(1):42-8. doi: 10.1097/GCO.0000000000000243. Review. PubMed PMID: 26642065.
20: Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5231-6. doi: 10.1073/pnas.1424313112. PubMed PMID: 25848011; PubMed Central PMCID: PMC4413320.
Reference：
2: Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. PubMed PMID: 27336726.
3: Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. PubMed PMID: 27542767.
4: Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Review. PubMed PMID: 27493615; PubMed Central PMCID: PMC4960359.
5: Ribociclib Lengthens Breast Cancer Survival. Cancer Discov. 2016 Dec;6(12):1299. PubMed PMID: 27810861.
6: Aristizabal Prada ET, Noelting S, Spoettl G, Maurer J, Auernhammer CJ. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology. 2017 Feb 23. doi: 10.1159/000463386. [Epub ahead of print] PubMed PMID: 28226315.
7: de Gramont A, Herrera A, de Gramont A. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288-289. PubMed PMID: 28102649.
8: Araki K, Miyoshi Y. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288. PubMed PMID: 28102647.
9: Hortobagyi GN. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):289. doi: 10.1056/NEJMc1615255. PubMed PMID: 28099830.
10: Burki TK. Ribociclib in HR-positive, HER2-negative breast cancer. Lancet Oncol. 2016 Nov;17(11):e482. doi: 10.1016/S1470-2045(16)30502-2. PubMed PMID: 27746106.
11: Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, Wei W, Dugger TC, Knudsen E, Arteaga CL. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017 Mar 1. pii: canres.2653.2016. doi: 10.1158/0008-5472.CAN-16-2653. [Epub ahead of print] PubMed PMID: 28249908.
12: Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V. [Cell cycle inhibitors in endocrine receptor positive breast cancer]. Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. French. PubMed PMID: 28126188.
13: Wood A, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King F, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris J, Mosse YP. Dual ALK and CDK4/6 inhibition demonstrates on-target synergy against neuroblastoma. Clin Cancer Res. 2016 Dec 16. pii: clincanres.1114.2016. [Epub ahead of print] PubMed PMID: 27986745.
14: Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin Cancer Res. 2016 Oct 11. doi: 10.1158/1078-0432.CCR-16-1131. [Epub ahead of print] PubMed PMID: 27729458.
15: Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015 Dec 18;10(12):2680-6. doi: 10.1021/acschembio.5b00368. PubMed PMID: 26390342; PubMed Central PMCID: PMC4684772.
16: O'Sullivan CC. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opin Pharmacother. 2016 Aug;17(12):1657-67. doi: 10.1080/14656566.2016.1201072. Review. PubMed PMID: 27322766.
17: Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer. 2016 Feb;16(1):8-17. doi: 10.1016/j.clbc.2015.07.005. Review. PubMed PMID: 26303211.
18: Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Review. PubMed PMID: 27017286.
19: Konecny GE. Cyclin-dependent kinase pathways as targets for women's cancer treatment. Curr Opin Obstet Gynecol. 2016 Feb;28(1):42-8. doi: 10.1097/GCO.0000000000000243. Review. PubMed PMID: 26642065.
20: Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5231-6. doi: 10.1073/pnas.1424313112. PubMed PMID: 25848011; PubMed Central PMCID: PMC4413320.
